Phibro Animal Health Co. (NASDAQ:PAHC) Receives Consensus Recommendation of “Strong Sell” from Analysts

Shares of Phibro Animal Health Co. (NASDAQ:PAHC) have been assigned an average rating of “Strong Sell” from the five research firms that are covering the firm, MarketBeat.com reports. Three research analysts have rated the stock with a sell recommendation and two have given a hold recommendation to the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $15.00.

A number of brokerages recently commented on PAHC. Bank of America raised their price target on Phibro Animal Health from $13.00 to $15.00 and gave the stock an “underperform” rating in a research report on Friday, August 30th. JPMorgan Chase & Co. initiated coverage on shares of Phibro Animal Health in a report on Tuesday, September 10th. They issued a “neutral” rating and a $22.00 target price on the stock.

Phibro Animal Health Trading Down 2.1 %

Shares of NASDAQ:PAHC opened at $21.53 on Tuesday. The company has a market capitalization of $872.03 million, a P/E ratio of 67.28, a P/E/G ratio of 1.70 and a beta of 0.52. The company has a debt-to-equity ratio of 1.79, a current ratio of 2.94 and a quick ratio of 1.64. The business’s 50 day simple moving average is $18.99 and its 200 day simple moving average is $16.68. Phibro Animal Health has a 1 year low of $9.40 and a 1 year high of $22.31.

Phibro Animal Health Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, September 25th. Stockholders of record on Wednesday, September 4th will be paid a $0.12 dividend. The ex-dividend date is Wednesday, September 4th. This represents a $0.48 dividend on an annualized basis and a dividend yield of 2.23%. Phibro Animal Health’s payout ratio is currently 150.00%.

Insider Buying and Selling

In related news, Director E Thomas Corcoran bought 5,000 shares of the business’s stock in a transaction on Wednesday, September 4th. The shares were purchased at an average price of $20.02 per share, for a total transaction of $100,100.00. Following the completion of the transaction, the director now directly owns 25,000 shares of the company’s stock, valued at approximately $500,500. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. 50.06% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Phibro Animal Health

Large investors have recently modified their holdings of the business. CWM LLC grew its holdings in Phibro Animal Health by 89.8% in the second quarter. CWM LLC now owns 2,188 shares of the company’s stock worth $37,000 after purchasing an additional 1,035 shares during the period. Fidelis Capital Partners LLC bought a new position in shares of Phibro Animal Health during the first quarter valued at about $46,000. China Universal Asset Management Co. Ltd. lifted its position in shares of Phibro Animal Health by 65.0% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 3,888 shares of the company’s stock worth $50,000 after buying an additional 1,531 shares in the last quarter. Quest Partners LLC bought a new stake in Phibro Animal Health during the fourth quarter worth $56,000. Finally, Summit Securities Group LLC purchased a new position in shares of Phibro Animal Health in the 2nd quarter worth about $83,000. Institutional investors own 99.34% of the company’s stock.

About Phibro Animal Health

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.